ClinicalTrials.gg
CompletedNCT03924986RATIONALE-309Updated Jan 31, 2025Results posted

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

A Phase 3 interventional study of Tislelizumab and Placebo in Recurrent or Metastatic Nasopharyngeal Cancer, sponsored by BeiGene. Completed at 37 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Primary conditionNasopharyngeal NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Nasopharyngeal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasopharyngeal Neoplasms with a site in China — 22 open to participants now, 30 under way, 6 of them phase 3. Nasopharyngeal Neoplasms · China.

Enrollment
21st of 73
263 · median 100
Started
2019
with 7 others
Phase 3
11 of 83
2 open now
Registered
52nd of 83
by date

Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, this one is the 21st largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2019, is one of 11 in phase 3, and was the 52nd registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

22 of the 83 studies in Nasopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasopharyngeal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal cancer.

03

Conditions studied

  • Recurrent or Metastatic Nasopharyngeal Cancer

Browse trials for

04

In context

Nasopharyngeal Neoplasms Reclassified

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

This study's enrollment of 263 is above the median of 60 across 178 interventional studies indexed under Nasopharyngeal Neoplasms.

Browse Nasopharyngeal Neoplasms studies →

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Compared within Nasopharyngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Able to provide written and can understand and agree to comply with the requirements of the study and the schedule of assessments
  2. Aged between 18 to 75 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)
  3. or cytologically confirmed, recurrent or NPC
  4. Participants must be able to provide fresh or archival tumor tissues (formalin-fixed paraffin-embedded [FFPE] blocks or approximately 10 [≥ 6] freshly cut unstained FFPE slides) with an associated pathological report. The archival tumor tissues must be collected within 2 years before screening. In the absence of sufficient archival tumor tissues, a fresh of a tumor lesion at baseline is mandatory
  5. (ECOG) performance status ≤ 1
  6. Must have ≥ 1 as defined per v1.1
  7. Must be treatment-naive for recurrent or metastatic NPC.

Key Exclusion Criteria:

  1. Participants with locally recurrence suitable for curative surgery or radiotherapy
  2. Received any approved systemic anticancer therapy, including hormonal therapy, within 28 days prior to initiation of study treatment. The following exception is allowed:

    • Palliative radiotherapy for bone metastases or soft tissue lesions should be completed > 7 days prior to baseline imaging.
  3. Has received any immunotherapy (including but not limited to interferons, interleukin 2, tumor necrosis factor interleukin, and thymoxin) or any therapies within 14 days or 5 half-lives (whichever is longer) of randomization
  4. Received prior therapies targeting programmed cell death protein-1 () or programmed cell death protein ligand-1 (PD-L1)
  5. Active or uncontrolled, untreated
  6. Active diseases or history of autoimmune diseases that may relapse
  7. Any active ≤ 2 years before randomization except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Arm A: Tislelizumab + Gemcitabine + Cisplatin

    Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks (Q3W), gemcitabine 1 g/m\^2 IV on days 1 and 8 of each 21-day cycle and cisplatin 80 mg/m\^2 IV on day 1 of each cycle for 4 to 6 treatment cycles. Participants may have received treatment for longer at the Investigator's discretion until disease progression. Participants with confirmed disease progression may have continued to receive tislelizumab monotherapy.

    Drug: Tislelizumab · Drug: Gemcitabine · Drug: Cisplatin

  • Placebo comparator
    Arm B: Placebo + Gemcitabine + Cisplatin

    Participants received placebo IV once every 3 weeks, gemcitabine 1 g/m\^2 IV on days 1 and 8 of each 21-day cycle and cisplatin 80 mg/m\^2 IV on day 1 of each cycle for 4 to 6 treatment cycles. Participants may have received treatment for longer at the Investigator's discretion until disease progression. Participants with confirmed disease progression may have crossed over to receive tislelizumab 200 mg IV Q3W monotherapy.

    Drug: Placebo · Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • 200 mg intravenously (IV) once every 3 weeks (Q3W)

    Also known as: BGB-A317

  • DrugPlacebo

    Placebo to match tislelizumab (administered intravenously Q3W)

  • 1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles

  • 80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.

07

What researchers measure

Primary outcomes

  1. Progression-free Survival as Assessed by the Independent Review Committee (IRC)

    Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS.

    Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)

Secondary outcomes

  1. Overall Response Rate (ORR) as Assessed by the IRC

    Defined as the percentage of participants who had complete response or partial response as assessed by the IRC per RECIST v1.1 in all randomized participants with measurable disease at Baseline.

    Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)

  2. Duration of Response (DOR) as Assessed by the IRC

    Defined as the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever occurred first, as assessed by the IRC per RECIST v1.1 in all randomized participants with documented objective responses.

    Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)

  3. Overall Survival (OS) as Assessed by the IRC

    Defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Through study completion data cut-off date of December 8th, 2023 or last available date showing participants alive (maximum time on study follow-up was 53 months)

  4. PFS as Assessed by the Investigator

    Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per RECIST v1.1.

    Time frame: Through the interim analysis data cut-off date of March 26th, 2021 (up to approximately 23 months)

  5. Progression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator

    Defined as the time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Through the study completion data cut-off date of December 8th, 2023 (maximum time on study follow-up was 53 months)

  6. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

    Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 (Each cycle is 21 days)

  7. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score

    The QLQ-H\&N35 consists of thirty-five questions that are associated with eighteen symptom scales (pain, swallowing, senses, speech, social eating, social contact, sexuality, problem with teeth, problem opening mouth, dry mouth, problem with sense smell, cough, felt ill, pain med, nutritional supplements, feeding tube, weight loss and weight gain).. Raw scores are transformed into a 0 to 100 scale via linear transformation. The index score is calculated as an average of the 18 symptom scales. A negative change from baseline score indicates improvement in symptoms.

    Time frame: Baseline to Cycle 6 (Each cycle is 21 days)

  8. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, vital signs, electrocardiograms (ECGs), and physical examinations (PEs ), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. For Arm B, only adverse events reported prior to participants crossing over to receive tislelizumab monotherapy are included.

    Time frame: From first dose to 30 days after last dose or new anticancer therapy, or until Dec 8, 2023 data cut-off; max treatment duration: 231 weeks (Arm A), 202 weeks (Arm B).

08

Results

Posted Jan 31, 2025

Participant flow

Participants were enrolled in multiple study centers in China, Thailand, and Taiwan. The first participant was consented on March 27th 2019, and the last participant completed on December 8th 2023.

Participant flow — Overall Study
MilestoneArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Started131132
Treated131132
Crossed over to tislelizumab070
Completed00
Not completed131132
Withdrew: Death5766
Withdrew: Study concluded by sponsor5141
Withdrew: Withdrawal by subject1520
Withdrew: Lost to follow-up75
Withdrew: Miscellaneous10

Outcome measures

PrimaryProgression-free Survival as Assessed by the Independent Review Committee (IRC)

Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS.

Time frame:
Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Reported as:
Median · Months
Progression-free Survival as Assessed by the Independent Review Committee (IRC)
MonthsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Progression-free Survival as Assessed by the Independent Review Committee (IRC)9.2 (7.6 to 10.1)7.4 (5.6 to 7.5)
Statistical analysis
  • Arm A: Tislelizumab + Gemcitabine + Cisplatin vs Arm B: Placebo + Gemcitabine + Cisplatin · Hazard ratio (hr): 0.52 · 95% CI 0.38 to 0.73Estimated using a Cox proportional hazards model with Efron's method for tied events, with Arm B as the reference group. The analysis was stratified by gender and liver metastases status.
SecondaryOverall Response Rate (ORR) as Assessed by the IRC

Defined as the percentage of participants who had complete response or partial response as assessed by the IRC per RECIST v1.1 in all randomized participants with measurable disease at Baseline.

Time frame:
Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by the IRC
percentage of participantsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Overall Response Rate (ORR) as Assessed by the IRC69.5 (60.8 to 77.2)55.3 (46.4 to 64.0)
Statistical analysis
  • Arm A: Tislelizumab + Gemcitabine + Cisplatin vs Arm B: Placebo + Gemcitabine + Cisplatin · Odds ratio (or): 1.85 · 95% CI 1.11 to 3.07
SecondaryDuration of Response (DOR) as Assessed by the IRC

Defined as the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever occurred first, as assessed by the IRC per RECIST v1.1 in all randomized participants with documented objective responses.

Time frame:
Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Reported as:
Median · months
Duration of Response (DOR) as Assessed by the IRC
monthsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Duration of Response (DOR) as Assessed by the IRC8.5 (6.5 to NA)6.1 (4.7 to 6.2)
SecondaryOverall Survival (OS) as Assessed by the IRC

Defined as the time from the date of randomization to the date of death due to any cause.

Time frame:
Through study completion data cut-off date of December 8th, 2023 or last available date showing participants alive (maximum time on study follow-up was 53 months)
Reported as:
Median · Months
Overall Survival (OS) as Assessed by the IRC
MonthsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Overall Survival (OS) as Assessed by the IRC45.3 (33.4 to NA)31.8 (25.0 to NA)
Statistical analysis
  • Arm A: Tislelizumab + Gemcitabine + Cisplatin vs Arm B: Placebo + Gemcitabine + Cisplatin · Hazard ratio (hr): 0.73 · 95% CI 0.51 to 1.05Estimated using a Cox proportional hazards model with Efron's method for tied events, with Arm B as the reference group. The analysis was stratified by gender and liver metastases status.
SecondaryPFS as Assessed by the Investigator

Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per RECIST v1.1.

Time frame:
Through the interim analysis data cut-off date of March 26th, 2021 (up to approximately 23 months)
Reported as:
Median · months
PFS as Assessed by the Investigator
monthsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
PFS as Assessed by the Investigator9.8 (7.8 to 11.9)7.6 (6.6 to 7.8)
Statistical analysis
  • Arm A: Tislelizumab + Gemcitabine + Cisplatin vs Arm B: Placebo + Gemcitabine + Cisplatin · Hazard ratio (hr): 0.54 · 95% CI 0.38 to 0.76Estimated using a Cox proportional hazards model with Efron's method for tied events, with Arm B as the reference group. The analysis was stratified by gender and liver metastases status.
SecondaryProgression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator

Defined as the time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Through the study completion data cut-off date of December 8th, 2023 (maximum time on study follow-up was 53 months)
Reported as:
Median · months
Progression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator
monthsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Progression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator45.3 (31.5 to NA)20.5 (13.9 to 27.2)
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 (Each cycle is 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
score on a scaleArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status0.2 ± 25.18-0.1 ± 20.72
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score

The QLQ-H\&N35 consists of thirty-five questions that are associated with eighteen symptom scales (pain, swallowing, senses, speech, social eating, social contact, sexuality, problem with teeth, problem opening mouth, dry mouth, problem with sense smell, cough, felt ill, pain med, nutritional supplements, feeding tube, weight loss and weight gain).. Raw scores are transformed into a 0 to 100 scale via linear transformation. The index score is calculated as an average of the 18 symptom scales. A negative change from baseline score indicates improvement in symptoms.

Time frame:
Baseline to Cycle 6 (Each cycle is 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score
score on a scaleArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score-0.3 ± 6.40-0.3 ± 7.17
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, vital signs, electrocardiograms (ECGs), and physical examinations (PEs ), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. For Arm B, only adverse events reported prior to participants crossing over to receive tislelizumab monotherapy are included.

Time frame:
From first dose to 30 days after last dose or new anticancer therapy, or until Dec 8, 2023 data cut-off; max treatment duration: 231 weeks (Arm A), 202 weeks (Arm B).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + Cisplatin
TEAEs133129
SAEs4746

Adverse events

Collected over From first dose to 30 days after the last dose or initiation of a new anticancer therapy, maximum duration of treatment was 231 weeks in Arm A and 202 weeks in Arm B.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Tislelizumab + Gemcitabine + Cisplatin57/133 (42.9%)47/133 (35.3%)133/133 (100%)
Arm B: Placebo + Gemcitabine + Cisplatin31/130 (23.8%)46/130 (35.4%)129/130 (99.2%)
Post Crossover Tislelizumab35/70 (50%)15/70 (21.4%)60/70 (85.7%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinPost Crossover Tislelizumab
Platelet count decreasedInvestigations9/13314/1300/70
Neutrophil count decreasedInvestigations3/1336/1300/70
AnaemiaBlood and lymphatic system disorders3/1335/1301/70
White blood cell count decreasedInvestigations3/1335/1300/70
LeukopeniaBlood and lymphatic system disorders0/1334/1300/70
PneumoniaInfections and infestations2/1334/1301/70
ThrombocytopeniaBlood and lymphatic system disorders4/1333/1300/70
SepsisInfections and infestations4/1330/1300/70
Cerebral infarctionNervous system disorders0/1331/1302/70
NeutropeniaBlood and lymphatic system disorders1/1332/1300/70
Most frequent other events
Showing 10 of 118
Most frequent other events
EventArm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinPost Crossover Tislelizumab
AnaemiaBlood and lymphatic system disorders114/133117/13019/70
NauseaGastrointestinal disorders78/13394/1306/70
White blood cell count decreasedInvestigations81/13381/1308/70
Neutrophil count decreasedInvestigations80/13376/1306/70
Platelet count decreasedInvestigations68/13376/1301/70
VomitingGastrointestinal disorders55/13368/1304/70
Decreased appetiteMetabolism and nutrition disorders64/13365/1304/70
ConstipationGastrointestinal disorders46/13360/13011/70
LeukopeniaBlood and lymphatic system disorders46/13344/1302/70
NeutropeniaBlood and lymphatic system disorders46/13338/1301/70

Baseline characteristics

The Intent to Treat (ITT) analysis set included all participants randomized to the study.

Age, Continuous
Age, Continuous(years)Arm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinTotal
Mean49.0 ± 10.6249.5 ± 10.7649.3 ± 10.67
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinTotal
Female282957
Male103103206
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Arm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinTotal
China122126248
Thailand516
Taiwan459
Baseline Target Lesions Sum of Diameters Assessed by Investigator (mm)
Baseline Target Lesions Sum of Diameters Assessed by Investigator (mm)(Millimeters (mm))Arm A: Tislelizumab + Gemcitabine + CisplatinArm B: Placebo + Gemcitabine + CisplatinTotal
Mean65.49 ± 49.00457.56 ± 40.38961.51 ± 44.978
09

Study locations

37 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 400030, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, Chongqing 404000, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
    Guangzhou, Guangdong 510000, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
    Guangzhou, Guangdong 510405, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524000, China
  • The Peoples Hospital of Zhongshan City
    Zhongshan, Guangdong 528403, China
  • The Fifth Affiliated Hospital Sun Yat Sen University
    Zhuhai, Guangdong 519000, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Hainan General Hospital
    Haikou, Hainan 570206, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 201203, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
  • Sichuan Cancer Hospital and Institute
    Chengdu, Sichuan 610041, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Changhua Christian Hospital
    Changhua, 50006, Taiwan
  • Veterans General Hospital Taichung
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Ramathibodi Hospital Mahidol University Hematology
    Bangkok, 10400, Thailand
  • Songklanagarind Hospital (Prince of Songkhla University)
    Hat Yai, 90110, Thailand
  • Srinagarind Hospital (Khon Kaen University)
    Muang, 40002, Thailand
  • Maharaj Nakorn Chiang Mai Hospital (Chiang Mai University)
    Muang, 50200, Thailand
10

References and documents

Publications

  • Zhang L, Liu T, Wang H, Shi S, Yang Y. A Phase 3 Trial in Progress Comparing Tislelizumab Plus Chemotherapy With Placebo Plus Chemotherapy in Chinese Patients With Recurrent or Metastatic Nasopharyngeal Cancer. Abstract published at: 22nd Annual Meeting of the Chinese Society of Clinical Oncology; September, 2019; Xiamen, China.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2021, 23 months.

Results were first posted in Jan 2025, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Apr 23, 2019
StartActual
Mar 27, 2019
Primary completionActual
Mar 26, 2021
CompletionActual
Dec 8, 2023
Results first posted
Jan 31, 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03924986
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Mar 27, 2019
Primary completion
Mar 26, 2021
Completion
Dec 8, 2023
Results posted
Jan 31, 2025
Last update
Jan 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion